In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Corbus Pharmaceuticals, with a price target of $53.00. The company’s shares closed yesterday at $14.52.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jones covers the Healthcare sector, focusing on stocks such as Corbus Pharmaceuticals, Perspective Therapeutics, and Astria Therapeutics. According to TipRanks, Jones has an average return of 0.0% and a 39.27% success rate on recommended stocks.
Corbus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $43.50, which is a 199.59% upside from current levels. In a report released yesterday, B. Riley Securities also reiterated a Buy rating on the stock with a $28.00 price target.
CRBP market cap is currently $177.9M and has a P/E ratio of -3.05.
Read More on CRBP:
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)